See more : Qutoutiao Inc. (QTT) Income Statement Analysis – Financial Results
Complete financial analysis of AVITA Medical, Inc. (RCEL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AVITA Medical, Inc., a leading company in the Medical – Devices industry within the Healthcare sector.
You may be interested
- 361 Degrees International Limited (1361.HK) Income Statement Analysis – Financial Results
- AES Indiana (IPWLK) Income Statement Analysis – Financial Results
- Superior Resources Limited (SPQ.AX) Income Statement Analysis – Financial Results
- Duro Felguera, S.A. (0F7F.L) Income Statement Analysis – Financial Results
- Lumina Gold Corp. (LUM.V) Income Statement Analysis – Financial Results
AVITA Medical, Inc. (RCEL)
About AVITA Medical, Inc.
AVITA Medical Inc. operates as a commercial-stage regenerative tissue company in the United States, Australia, and the United Kingdom. It offers regenerative products to address unmet medical needs in burn injuries, trauma injuries, chronic wounds, and dermatological and aesthetics indications, including vitiligo. The company's patented and proprietary platform technology provides treatment solutions derived from the regenerative properties of a patient's own skin. Its lead product is RECELL System, a device that enables healthcare professionals to produce a suspension of Spray-On Skin cells using a small sample of the patient's own skin for use in the treatment of acute thermal burns in patients eighteen years and older. The company has a research collaboration with the University of Colorado School of Medicine to establish pre-clinical proof-of-concept for a spray-on treatment of genetically corrected cells; and a research collaboration with Houston Methodist Research Institute to explore molecular reversal of cellular aging through a novel cell suspension delivery system. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical Inc. in December 2020. AVITA Medical Inc. was incorporated in 2000 and is based in Valencia, California.
| Metric | 2022 | 2020 | 2019 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2003 | 2002 | 2001 | 2000 | 1999 | 1998 | 1997 | 1996 | 1995 | 1994 | 1993 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 50.56M | 14.26M | 20.67M | 1.26M | 1.18M | 1.00M | 985.65K | 2.68M | 2.81M | 3.35M | 3.34M | 2.30M | 2.37M | 1.20M | 790.99K | 883.39K | 389.08K | 194.32K | 0.00 | 0.00 | 0.00 | 582.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 8.87M | 2.97M | 4.31M | 737.70K | 505.64K | 401.57K | 289.20K | 670.89K | 676.50K | 952.85K | 972.78K | 669.45K | 824.23K | 492.31K | 1.13M | 1.06M | 940.26K | 98.98K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 41.69M | 11.29M | 16.36M | 517.47K | 675.00K | 600.44K | 696.45K | 2.01M | 2.14M | 2.40M | 2.36M | 1.63M | 1.54M | 711.35K | -337.70K | -176.85K | -551.18K | 95.34K | 0.00 | 0.00 | 0.00 | 582.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 82.45% | 79.16% | 79.16% | 41.23% | 57.17% | 59.92% | 70.66% | 75.00% | 75.97% | 71.58% | 70.84% | 70.85% | 65.18% | 59.10% | -42.69% | -20.02% | -141.66% | 49.06% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 20.35M | 8.46M | 13.28M | 8.45M | 6.27M | 3.46M | 3.77M | 2.15M | 2.60M | 969.11K | 255.54K | 164.79K | 181.85K | 163.83K | 620.67K | 1.33M | 425.97K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 34.27M | 34.62M | 46.77M | 12.70M | 0.00 | 6.51M | 2.45M | 4.27M | 5.45M | 5.34M | 5.42M | 3.40M | 3.87M | 3.98M | 5.36M | 5.64M | 2.21M | 725.90K | 480.40K | 569.49K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Selling & Marketing | 32.19M | 14.81M | 22.76M | 6.59M | 5.20M | 3.46M | 3.21M | 2.63M | 3.39M | 2.93M | 2.15M | 1.15M | 1.37M | 1.39M | 1.92M | 1.90M | 838.56K | 122.35K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 66.46M | 49.43M | 70.61M | 21.21M | 13.90M | 10.93M | 5.68M | 7.09M | 8.92M | 8.44M | 7.57M | 4.55M | 5.24M | 5.37M | 7.28M | 7.54M | 3.05M | 848.25K | 480.40K | 569.49K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Other Expenses | 0.00 | 686.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 852.27K | 886.45K | 41.73K | 5.88K | 4.27M | 85.29K | 240.35K | -1.28M | -24.61K | -2.08M | 28.27K | -956.00K | -1.56M | 1.52M | 910.39K | 40.34K | 16.93K |
| Operating Expenses | 80.78M | 53.97M | 77.21M | 19.15M | 13.35M | 11.95M | 9.26M | 8.83M | 10.77M | 10.66M | 7.89M | 5.23M | 5.91M | 5.75M | 8.75M | 9.62M | 4.87M | 169.38K | 670.01K | 76.87K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Cost & Expenses | 89.65M | 56.94M | 81.51M | 19.88M | 13.85M | 12.36M | 9.55M | 9.50M | 11.45M | 11.61M | 8.86M | 5.90M | 6.74M | 6.25M | 9.88M | 10.68M | 5.81M | 268.36K | 670.01K | 76.87K | 235.70K | 371.78K | 97.16K | 138.81K | 126.55K | 278.48K | 207.93K |
| Interest Income | 23.50K | 0.00 | 47.82K | 28.37K | 110.96K | 110.34K | 45.42K | 160.33K | 412.26K | 497.99K | 124.99K | 124.70K | 270.11K | 668.21K | 543.41K | 520.50K | 201.65K | 145.15K | 126.13K | 195.94K | 6.81K | 609.80 | 4.20K | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 33.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 12.90K | 37.65K | 78.50K | 53.20K | 8.55M | 4.86K | 9.95K | 2.26K | 3.57 | 4.97M | 576.36K | 2.07M | 2.19M | 258.33K | 1.16M | 775.70 | -191.00K |
| Depreciation & Amortization | 1.46M | 465.00K | 0.00 | 105.45K | 139.70K | 83.72K | 62.62K | 63.71K | 121.92K | 569.23K | 650.88K | 517.57K | 491.49K | 221.96K | 852.62K | 745.94K | 702.81K | 111.83K | 189.60K | 76.87K | 595.35K | -923.38K | -2.19M | 578.99K | -1.16M | -1.96M | 49.44K |
| EBITDA | -39.57M | -41.53M | -61.17M | -18.55M | -12.53M | -11.27M | -8.68M | -6.76M | -8.51M | -5.62M | -3.89M | -2.08M | -3.57M | -4.15M | -3.69M | -8.45M | -4.27M | -1.39M | -390.45K | 575.84K | 359.65K | 582.97K | -2.29M | 440.17K | -1.29M | -2.23M | -158.49K |
| EBITDA Ratio | -78.26% | -291.16% | -295.97% | -1,478.04% | -1,061.34% | -1,124.79% | -880.69% | -251.79% | -302.36% | -167.75% | -116.76% | -90.46% | -150.78% | -344.42% | -466.58% | -956.13% | -1,097.89% | -717.25% | 0.00% | 0.00% | 0.00% | 100.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -40.40M | -42.68M | -61.84M | -18.70M | -12.67M | -11.35M | -8.74M | -6.82M | -8.63M | -6.19M | -4.38M | -2.59M | -4.06M | -4.37M | -4.54M | -9.19M | -4.97M | -1.62M | -1.29M | 498.37K | -235.70K | 1.51M | -97.16K | -138.81K | -126.55K | -278.48K | -207.93K |
| Operating Income Ratio | -79.91% | -299.23% | -299.23% | -1,489.88% | -1,073.17% | -1,133.14% | -887.04% | -254.16% | -306.69% | -184.73% | -131.31% | -113.00% | -171.55% | -362.86% | -574.37% | -1,040.57% | -1,278.53% | -832.34% | 0.00% | 0.00% | 0.00% | 258.39% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.29M | 686.00K | 946.20K | 43.24K | 110.96K | 110.34K | 222.97K | 160.33K | 412.26K | -1.57M | 3.23M | -1.82M | 41.73K | -7.58M | -4.55M | 85.29K | 240.35K | -1.58M | -735.53K | -1.16M | -567.08K | -956.00K | -1.56M | 1.52M | 911.13K | 99.29K | 158.49K |
| Income Before Tax | -39.12M | -42.03M | -60.90M | -18.66M | -12.56M | -11.24M | -8.52M | -6.66M | -8.22M | -7.76M | -2.18M | -5.34M | -4.14M | -12.00M | -13.09M | -9.20M | -4.98M | -1.51M | -1.29M | -1.63M | -812.06K | -563.08K | -2.29M | 184.42K | -1.29M | -2.18M | -16.93K |
| Income Before Tax Ratio | -77.36% | -294.65% | -294.65% | -1,486.44% | -1,063.77% | -1,122.13% | -864.42% | -248.18% | -292.04% | -231.47% | -65.24% | -232.33% | -174.86% | -997.23% | -1,655.44% | -1,041.12% | -1,281.08% | -775.96% | 0.00% | 0.00% | 0.00% | -96.59% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 52.88K | 4.00K | 5.80K | 1.45M | 1.05M | 971.88K | 653.67K | 1.51M | 128.05K | 87.76K | -90.09K | -330.41K | 78.50K | -342.23K | -316.55K | -311.92K | -7.13M | -2.69M | -2.53M | -2.94M | 576.36K | -923.38K | 2.19M | -581.57K | 1.16M | -238.92K | 208.61K |
| Net Income | -39.17M | -42.03M | -60.90M | -17.21M | -11.51M | -10.27M | -7.87M | -5.15M | -8.09M | -7.59M | -2.09M | -5.01M | -4.14M | -11.66M | -12.78M | -8.89M | -4.98M | -1.54M | -1.12M | -1.54M | -812.06K | -562.85K | -2.29M | 184.42K | -1.29M | -1.94M | -225.54K |
| Net Income Ratio | -77.47% | -294.68% | -294.68% | -1,370.83% | -974.99% | -1,025.14% | -798.10% | -191.84% | -287.49% | -226.42% | -62.54% | -217.95% | -174.86% | -968.80% | -1,615.42% | -1,005.81% | -1,281.08% | -794.76% | 0.00% | 0.00% | 0.00% | -96.55% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.57 | -2.07 | -3.00 | -1.84 | -1.72 | -2.06 | -2.23 | -1.58 | -2.69 | -3.19 | -1.53 | -3.93 | -3.75 | -16.51 | -3.24 | -3.43 | -3.14 | -1.92 | -0.56 | -0.80 | -1.32 | -2.25 | -48.58 | -0.74 | -27.28 | -42.11 | -5.06 |
| EPS Diluted | -1.57 | -2.07 | -3.00 | -1.85 | -1.72 | -2.06 | -2.23 | -1.58 | -2.69 | -3.19 | -1.53 | -3.93 | -3.75 | -16.51 | -3.24 | -3.43 | -3.14 | -1.92 | -0.56 | -0.80 | -1.32 | -2.25 | -48.58 | -0.74 | -27.28 | -42.11 | -5.06 |
| Weighted Avg Shares Out | 25.00M | 20.29M | 20.29M | 9.30M | 6.69M | 4.99M | 3.53M | 3.25M | 3.01M | 2.38M | 1.36M | 1.27M | 1.10M | 706.45K | 3.94M | 2.59M | 1.59M | 806.03K | 2.00M | 1.93M | 614.53K | 249.70K | 47.13K | 47.13K | 47.13K | 46.02K | 44.55K |
| Weighted Avg Shares Out (Dil) | 25.00M | 20.29M | 20.29M | 9.33M | 6.70M | 4.99M | 3.53M | 3.25M | 3.01M | 2.38M | 1.36M | 1.27M | 1.10M | 706.45K | 3.94M | 2.59M | 1.59M | 806.03K | 2.00M | 1.93M | 614.53K | 249.70K | 47.13K | 47.13K | 47.13K | 46.02K | 44.55K |
AVITA Medical to Present at the Piper Sandler 36ᵗʰ Annual Healthcare Conference
VALENCIA, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that Jim Corbett, Chief Executive Officer, will...
AVITA Medical Announces Exclusive Distribution Agreement to Expand to Australia and New Zealand
VALENCIA, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a company specializing in commercial-stage regenerative medicine and pioneering devices for wound care management and skin restoration, today announced it has entered into an exclusive...
AVITA Medical, Inc. (RCEL) Q3 2024 Earnings Call Transcript
AVITA Medical, Inc. (NASDAQ:RCEL ) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Jessica Ekeberg - Director, Investor Relations Jim Corbett - Chief Executive Officer David O'Toole - Chief Financial Officer Conference Call Participants Brooks...
AVITA Medical to Host Investor Webinar Briefing
VALENCIA, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor...
AVITA Medical Reports Third Quarter Financial Results
VALENCIA, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today reported financial results for the third quarter ended...
AVITA Medical to Announce Third Quarter 2024 Financial Results
AVITA Medical announced that it will report its third quarter 2024 financial results after the close of the U.S. financial markets on November 7, 2024.
AVITA Medical Headed For Its Most Important Report, I'm Extremely Bullish
AVITA Medical's RECELL GO offers superior wound healing with less donor skin required, reducing scarring and infection risk. It has no direct competition. RECELL GO streamlines the skin grafting process, saving time and money. New products like PermeaDerm and Cohealyx...
AVITA Medical to Present at 2024 Cantor Global Healthcare Conference
VALENCIA, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that David O'Toole, Chief Financial Officer, will...
AVITA Medical to Participate in Lake Street's 8th Annual Best Ideas Growth (BIG8) Conference
VALENCIA, Calif., Sept. 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that management will participate in Lake Street...
AVITA Medical: New Products, Same Old Cash Burn (Rating Downgrade)
RECELL GO's launch increased SG&A expenses, contributing to AVITA Medical, Inc.'s higher net losses in Q2 2024. Despite lowering its 2024 revenue guidance, AVITA Medical still anticipates significant year-over-year growth of 37-41%. AVITA Medical's cash runway is approximately nine months,...
Source: https://incomestatements.info
Category: Stock Reports